JP2010522210A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010522210A5 JP2010522210A5 JP2009554762A JP2009554762A JP2010522210A5 JP 2010522210 A5 JP2010522210 A5 JP 2010522210A5 JP 2009554762 A JP2009554762 A JP 2009554762A JP 2009554762 A JP2009554762 A JP 2009554762A JP 2010522210 A5 JP2010522210 A5 JP 2010522210A5
- Authority
- JP
- Japan
- Prior art keywords
- aliphatic
- optionally substituted
- compound according
- ring
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 146
- 125000001931 aliphatic group Chemical group 0.000 claims description 113
- 229910052736 halogen Inorganic materials 0.000 claims description 58
- 150000002367 halogens Chemical class 0.000 claims description 54
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 48
- 125000000623 heterocyclic group Chemical group 0.000 claims description 44
- 229920006395 saturated elastomer Polymers 0.000 claims description 44
- 229910052799 carbon Inorganic materials 0.000 claims description 35
- 229910052757 nitrogen Inorganic materials 0.000 claims description 31
- -1 COOR ′ Chemical group 0.000 claims description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 30
- 125000001424 substituent group Chemical group 0.000 claims description 29
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 27
- 125000003118 aryl group Chemical group 0.000 claims description 26
- 125000005843 halogen group Chemical group 0.000 claims description 26
- 229910052739 hydrogen Inorganic materials 0.000 claims description 26
- 125000001072 heteroaryl group Chemical group 0.000 claims description 25
- 125000004429 atom Chemical group 0.000 claims description 22
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 22
- 229910052717 sulfur Chemical group 0.000 claims description 21
- 125000005842 heteroatom Chemical group 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 18
- 125000002723 alicyclic group Chemical group 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 16
- 229910052760 oxygen Inorganic materials 0.000 claims description 16
- 208000035475 disorder Diseases 0.000 claims description 14
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 10
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 9
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 9
- 239000001301 oxygen Chemical group 0.000 claims description 9
- 239000011593 sulfur Chemical group 0.000 claims description 9
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 7
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 4
- 102000007072 Nerve Growth Factors Human genes 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 206010052779 Transplant rejections Diseases 0.000 claims description 4
- 229940124599 anti-inflammatory drug Drugs 0.000 claims description 4
- 230000001028 anti-proliverative effect Effects 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 239000012472 biological sample Substances 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 4
- 125000001188 haloalkyl group Chemical group 0.000 claims description 4
- 239000002955 immunomodulating agent Substances 0.000 claims description 4
- 229940121354 immunomodulator Drugs 0.000 claims description 4
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 4
- 239000003018 immunosuppressive agent Substances 0.000 claims description 4
- 208000033065 inborn errors of immunity Diseases 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 239000003900 neurotrophic factor Substances 0.000 claims description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 4
- 208000028529 primary immunodeficiency disease Diseases 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 3
- 206010065040 AIDS dementia complex Diseases 0.000 claims description 2
- 201000004384 Alopecia Diseases 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 208000019838 Blood disease Diseases 0.000 claims description 2
- 208000020084 Bone disease Diseases 0.000 claims description 2
- 208000020446 Cardiac disease Diseases 0.000 claims description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- 206010020880 Hypertrophy Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 208000014767 Myeloproliferative disease Diseases 0.000 claims description 2
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 230000000172 allergic effect Effects 0.000 claims description 2
- 208000030961 allergic reaction Diseases 0.000 claims description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 2
- 239000003443 antiviral agent Substances 0.000 claims description 2
- 208000010216 atopic IgE responsiveness Diseases 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 125000002837 carbocyclic group Chemical group 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 210000004413 cardiac myocyte Anatomy 0.000 claims description 2
- 230000000973 chemotherapeutic effect Effects 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 230000001066 destructive effect Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 208000024908 graft versus host disease Diseases 0.000 claims description 2
- 208000024963 hair loss Diseases 0.000 claims description 2
- 230000003676 hair loss Effects 0.000 claims description 2
- 208000019622 heart disease Diseases 0.000 claims description 2
- 208000014951 hematologic disease Diseases 0.000 claims description 2
- 208000018706 hematopoietic system disease Diseases 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 208000028867 ischemia Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 208000019423 liver disease Diseases 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 230000002062 proliferating effect Effects 0.000 claims description 2
- 230000010410 reperfusion Effects 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 201000000980 schizophrenia Diseases 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 238000002054 transplantation Methods 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 5
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 4
- 125000006592 (C2-C3) alkenyl group Chemical group 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 10
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 10
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 8
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 4
- 125000004043 oxo group Chemical group O=* 0.000 description 4
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 description 2
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 description 2
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- XSXHWVKGUXMUQE-UHFFFAOYSA-N osmium dioxide Inorganic materials O=[Os]=O XSXHWVKGUXMUQE-UHFFFAOYSA-N 0.000 description 2
- 102000015617 Janus Kinases Human genes 0.000 description 1
- 108010024121 Janus Kinases Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- UHCBBWUQDAVSMS-UHFFFAOYSA-N fluoroethane Chemical compound CCF UHCBBWUQDAVSMS-UHFFFAOYSA-N 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91946907P | 2007-03-22 | 2007-03-22 | |
| US60/919,469 | 2007-03-22 | ||
| PCT/US2008/057797 WO2008116139A2 (en) | 2007-03-22 | 2008-03-21 | N-heterocyclic compounds useful as inhibitors of janus kinases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013228193A Division JP2014024867A (ja) | 2007-03-22 | 2013-11-01 | Ｊａｋ阻害薬として有用なｎ−複素環式化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010522210A JP2010522210A (ja) | 2010-07-01 |
| JP2010522210A5 true JP2010522210A5 (enExample) | 2013-12-19 |
| JP5642973B2 JP5642973B2 (ja) | 2014-12-17 |
Family
ID=39730636
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009554762A Expired - Fee Related JP5642973B2 (ja) | 2007-03-22 | 2008-03-21 | Ｊａｋ阻害薬として有用なｎ−複素環式化合物 |
| JP2013228193A Withdrawn JP2014024867A (ja) | 2007-03-22 | 2013-11-01 | Ｊａｋ阻害薬として有用なｎ−複素環式化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013228193A Withdrawn JP2014024867A (ja) | 2007-03-22 | 2013-11-01 | Ｊａｋ阻害薬として有用なｎ−複素環式化合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20100160287A1 (enExample) |
| EP (1) | EP2144878A2 (enExample) |
| JP (2) | JP5642973B2 (enExample) |
| KR (1) | KR20090129488A (enExample) |
| CN (1) | CN101778825A (enExample) |
| AU (1) | AU2008228768A1 (enExample) |
| CA (1) | CA2681516A1 (enExample) |
| IL (1) | IL201064A0 (enExample) |
| MX (1) | MX2009010127A (enExample) |
| WO (1) | WO2008116139A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101622248B (zh) | 2006-12-29 | 2013-04-17 | 里格尔制药公司 | 用作axl抑制剂的n3-杂芳基取代的三唑和n5-杂芳基取代的三唑 |
| TW201100441A (en) | 2009-06-01 | 2011-01-01 | Osi Pharm Inc | Amino pyrimidine anticancer compounds |
| CN102471345A (zh) * | 2009-07-15 | 2012-05-23 | 雅培制药有限公司 | 激酶的吡咯并吡嗪抑制剂 |
| CA2788450A1 (en) | 2009-12-30 | 2011-07-07 | Arqule, Inc. | Substituted naphthalenyl-pyrimidine compounds |
| JP2013147428A (ja) * | 2010-04-27 | 2013-08-01 | Dainippon Sumitomo Pharma Co Ltd | 新規２−ヘテロアリール単環ピリミジン誘導体 |
| EP2611789A1 (en) | 2010-09-01 | 2013-07-10 | Ambit Biosciences Corporation | Quinazoline compounds and methods of use thereof |
| WO2012074951A1 (en) | 2010-11-29 | 2012-06-07 | OSI Pharmaceuticals, LLC | Macrocyclic kinase inhibitors |
| JP2014500277A (ja) | 2010-12-09 | 2014-01-09 | アムジエン・インコーポレーテツド | Ｐｉｍ阻害剤としての二環式化合物 |
| WO2012129338A1 (en) | 2011-03-22 | 2012-09-27 | Amgen Inc. | Azole compounds as pim inhibitors |
| ES2698847T3 (es) | 2011-07-07 | 2019-02-06 | Merck Patent Gmbh | Azaheterociclos sustituidos para el tratamiento del cáncer |
| US9089574B2 (en) | 2011-11-30 | 2015-07-28 | Emory University | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections |
| WO2014126954A1 (en) * | 2013-02-13 | 2014-08-21 | OSI Pharmaceuticals, LLC | Regioselective synthesis of substituted pyrimidines |
| CA3129665A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| CA3156007A1 (en) | 2019-09-27 | 2021-04-01 | Disc Medicine, Inc. | METHODS OF TREATING MYELOFIBROSE AND ASSOCIATED CONDITIONS |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| ES3075793T3 (en) | 2020-05-13 | 2026-08-07 | Disc Medicine Inc | Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis |
| AU2021273014A1 (en) | 2020-05-13 | 2022-11-17 | AbbVie Deutschland GmbH & Co. KG | Anti-hemojuvelin (HJV) antibodies for treating anemia of chronic disease |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3867386A (en) * | 1969-11-04 | 1975-02-18 | American Home Prod | 5-amino-2,6-substituted-7h-pyrrolo(2,3-d)pyrimidines and related compounds |
| US3631036A (en) * | 1969-11-04 | 1971-12-28 | American Home Prod | 5-amino-2 6-substituted-7h-pyrrolo(2 3-d) pyrimidines and related compounds |
| IL117659A (en) * | 1995-04-13 | 2000-12-06 | Dainippon Pharmaceutical Co | Substituted 2-phenyl pyrimidino amino acetamide derivative process for preparing the same and a pharmaceutical composition containing same |
| ZA977427B (en) * | 1996-09-04 | 1998-03-02 | Dainippon Pharmaceutical Co | 2,4-disubstituted pyrimidine derivative, process for preparing the same, and a pharmaceutical composition containing the same. |
| JP2003146987A (ja) * | 1999-05-31 | 2003-05-21 | Dainippon Pharmaceut Co Ltd | ２−アリールプリン−９−アセトアミド誘導体 |
| ATE250053T1 (de) * | 1999-07-15 | 2003-10-15 | Pharmacopeia Inc | Bradikinin b1 rezeptor antagonisten |
| US7037916B2 (en) * | 1999-07-15 | 2006-05-02 | Pharmacopeia Drug Discovery, Inc. | Pyrimidine derivatives as IL-8 receptor antagonists |
| EP1506189A1 (en) * | 2002-04-26 | 2005-02-16 | Vertex Pharmaceuticals Incorporated | Pyrrole derivatives as inhibitors of erk2 and uses thereof |
| AR042052A1 (es) * | 2002-11-15 | 2005-06-08 | Vertex Pharma | Diaminotriazoles utiles como inhibidores de proteinquinasas |
| WO2004069829A1 (en) * | 2003-01-10 | 2004-08-19 | Pharmacopeia Drug Discovery, Inc. | (2s)-2-((pyrimidin-4-yl)amino)-4-methylpentanoic acid aminoethylamid derivatives as il-8 receptor modulators for the treatment of atherosclerosis and rheumatoid arthritis |
| CL2004000409A1 (es) * | 2003-03-03 | 2005-01-07 | Vertex Pharma | Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu |
| ES2364340T3 (es) * | 2004-03-30 | 2011-08-31 | Vertex Pharmaceuticals Incorporated | Azaindoles útiles como inhibidores de jak y otras proteína quinasas. |
| DE602005023763D1 (de) * | 2004-11-04 | 2010-11-04 | Vertex Pharma | Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine |
| AU2005309566A1 (en) * | 2004-11-22 | 2006-06-01 | Vertex Pharmaceuticals Incorporated | Bicyclic inhibitors or Rho kinase |
| MX2007007330A (es) * | 2004-12-16 | 2007-10-04 | Vertex Pharma | Piridonas de utilidad como inhibidores de quinasas . |
| JP2008545660A (ja) * | 2005-05-20 | 2008-12-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼ阻害剤として有用なピロロピリジン化合物 |
| CN101801971A (zh) * | 2005-09-30 | 2010-08-11 | 沃泰克斯药物股份有限公司 | 可用作janus激酶抑制剂的脱氮嘌呤 |
| NZ592968A (en) * | 2006-01-17 | 2012-08-31 | Vertex Pharma | Azaindoles substituted with either triazine or pyrimidine useful as inhibitors of janus kinases consisting of JAK1, JAK2, JAK3, and TYK2 |
| CA2649995A1 (en) | 2006-04-26 | 2007-11-08 | Cancer Research Technology Limited | Amino-ethyl-amino-aryl (aeaa) compounds and their use |
| WO2008079346A1 (en) * | 2006-12-21 | 2008-07-03 | Vertex Pharmaceuticals Incorporated | 5-cyan0-4- (pyrrolo [2, 3b] pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors |
-
2008
- 2008-03-21 KR KR1020097022156A patent/KR20090129488A/ko not_active Withdrawn
- 2008-03-21 CN CN200880014699A patent/CN101778825A/zh active Pending
- 2008-03-21 EP EP08744172A patent/EP2144878A2/en not_active Withdrawn
- 2008-03-21 JP JP2009554762A patent/JP5642973B2/ja not_active Expired - Fee Related
- 2008-03-21 CA CA002681516A patent/CA2681516A1/en not_active Abandoned
- 2008-03-21 WO PCT/US2008/057797 patent/WO2008116139A2/en not_active Ceased
- 2008-03-21 MX MX2009010127A patent/MX2009010127A/es not_active Application Discontinuation
- 2008-03-21 AU AU2008228768A patent/AU2008228768A1/en not_active Abandoned
-
2009
- 2009-09-21 IL IL201064A patent/IL201064A0/en unknown
- 2009-09-22 US US12/564,156 patent/US20100160287A1/en not_active Abandoned
-
2011
- 2011-10-25 US US13/280,670 patent/US8686143B2/en not_active Expired - Fee Related
-
2013
- 2013-11-01 JP JP2013228193A patent/JP2014024867A/ja not_active Withdrawn
-
2014
- 2014-02-05 US US14/172,963 patent/US20140221336A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009532475A5 (enExample) | ||
| CA2765015C (en) | Deuterated isoindoline-1,3-dione derivatives as pde4 and tnf-alpha inhibitors | |
| TWI752155B (zh) | 芳香烴受體(AhR)調節劑化合物 | |
| RU2008143361A (ru) | Деазапурины в качестве ингибиторов янус-киназ | |
| JP2008545660A5 (enExample) | ||
| RU2011151085A (ru) | Азаиндолы, полезные в качестве ингибиторов янус-киназ | |
| JP2011507881A5 (enExample) | ||
| KR20210089716A (ko) | 질소 함유 축합 헤테로고리 shp2억제제 화합물, 제조방법 및 용도 | |
| RU2007147455A (ru) | Пирролопиридины, полезные в качестве ингибиторов протеинкиназы | |
| RU2006138040A (ru) | Азаиндолы, полезные в качестве ингибиторов jak и других протеинкиназ | |
| CA2924619C (en) | 4-azaindole derivatives | |
| RU2007132908A (ru) | Пирролопиримидины, применимые в качестве ингибиторов протеинкиназы | |
| RS56720B1 (sr) | Jedinjenja i kompozicije za lečenje parazitskih oboljenja | |
| EP2861600A1 (en) | Deuterated derivatives of ruxolitinib | |
| RU2012142550A (ru) | Производные пирролопиразина и их применение в качестве ингибиторов jak и syk | |
| Ashok et al. | Synthesis and anti-leishmanial evaluation of 1-phenyl-2, 3, 4, 9-tetrahydro-1H-β-carboline derivatives against Leishmania infantum | |
| RU2013148922A (ru) | Три- и тетрациклические пиразоло[3,4-в]пиридины в качестве антинеопластического средства | |
| JP2009526849A5 (enExample) | ||
| RU2006138621A (ru) | Азаиндолы, полезные в качестве ингибиторов rock и других протеинкиназ | |
| JP2010513285A5 (enExample) | ||
| JP2012524053A5 (enExample) | ||
| JP2011520832A5 (enExample) | ||
| HRP20161010T1 (hr) | C5ar antagonisti | |
| EP3253754B1 (en) | 2-phenyl-3h-imidazo[4,5-b]pyridine derivates useful as inhibitors of mammalian tyrosine kinase ror1 activity | |
| JP2013522275A5 (enExample) |